travellinglight/iStock via Getty Images
- Swedish biopharma BioArctic (OTCPK:BRCTF) announced Tuesday that the European Commission has approved Biogen (NASDAQ:BIIB) and Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) Alzheimer’s therapy Leqembi (lecanemab) to treat the early form of the memory-robbing disease.
- With the EU marketing authorization, the amyloid-targeting therapy will be